

SPOTLIGHT

TAPPING into PIPs: A new reporter reveals the origin of plasma membrane PI(3,4)P₂

Ivan Yudushkin

The membrane lipid phosphatidylinositol-3,4-bisphosphate (PI(3,4)P₂) is an important signaling effector, controlling both anabolic pathways and membrane trafficking. In this issue, Goulden et al. (2019). *J. Cell Biol.* <https://doi.org/10.1083/jcb.201809026> report a new PI(3,4)P₂ probe and show that plasma membrane PI(3,4)P₂ is a product of PI(3,4,5)P₃ dephosphorylation.

Phosphoinositide lipids direct membrane trafficking and coordinate the timing and localization of cellular signaling. The lipid products of phosphatidylinositol 3-kinase (PI3K), PI(3,4,5)P₃ and PI(3,4)P₂, are important regulators of signaling pathways that couple growth factor receptors to cellular anabolic pathways. Their accumulation due to mutations in PI3K or inactivation of the counteracting lipid phosphatases, such as PTEN, leads to hyperactivation of the downstream kinases Akt and mTORC1 and cellular transformation. While PI(3,4,5)P₃ had long been considered to play the major role in PI3K signaling, accumulating evidence indicates that PI(3,4)P₂ has distinct functions in the control of Akt (1) and mTORC1 activation (2), endocytosis (3), the formation of invadopodia, and cancer metastasis (4). Unlike PI(3,4,5)P₃, however, the cellular sources, dynamics, and functions of PI(3,4)P₂ remain poorly understood, largely due to a lack of tools to detect this rare lipid in cells. In this issue, Goulden et al. report the development and characterization of a genetically encoded fluorescent PI(3,4)P₂ reporter and propose that the major population of PI(3,4)P₂ at the plasma membrane derives from PI(3,4,5)P₃ dephosphorylation (5).

Lipid reporters are typically based on specific protein binding domains, tagged with a fluorescent protein. The probe reported by Goulden et al. is a triple tandem of the PI(3,4)P₂-specific C-terminal lipid-binding pleckstrin homology (cPH) domain of the protein TAPP1 (5). Such probes

are often optimized for avidity to their lipid ligands, for example, through mutagenesis or by fusion to additional protein modules serving to enhance their recruitment to the endocytic vesicles (6). Yet, an avidity that is too high could result in unspecific binding, prevent lipid degradation, and/or lead to dominant-negative effects on downstream signaling. Goulden et al. set a golden standard by carefully designing and characterizing the specificity, selectivity, and diffusion and off-rates of their probe, to ensure that it faithfully reports the true kinetics of PI(3,4)P₂ in a cell (5). Further, as an additional control, they developed an orthogonal optogenetic system to demonstrate that PI(3,4)P₂ is both necessary and sufficient for recruitment of the probe to the cellular compartments where it is produced.

With this sensitive, genetically encoded reporter, Goulden et al. (5) examined the kinetics and cellular sources of PI(3,4)P₂ in cells. Three synthetic routes could lead to PI(3,4)P₂ production: (a) direct phosphorylation of PI(4)P by class I PI3Ks; (b) direct phosphorylation of PI(4)P by class II PI3Ks; and (c) dephosphorylation of PI(3,4,5)P₃ by lipid 5-phosphatases. Chemical inhibition of class I PI3Ks resulted in a nearly complete depletion of PI(3,4)P₂, indicating that the latter likely derives from PI(3,4,5)P₃ and arguing against the involvement of class II PI3Ks. Consistently, depletion of PI(4,5)P₂ and PI(3,4,5)P₃ pools by recruitment of a 5-phosphatase INPP5E followed by direct phosphorylation of the resulting PI(4)P by class I PI3K resulted in

weaker and transient PI(3,4)P₂ production, suggesting that the plasma membrane pool of PI(3,4)P₂ is predominantly a product of direct PI(3,4,5)P₃ dephosphorylation by a 5-phosphatase, like SHIP1/2.

These results are satisfyingly consistent with those of a recent study that used a monomeric TAPP1 cPH domain conjugated to a hydrophobic environmentally sensitive organic fluorophore as a reporter for PI(3,4)P₂ (1). Distinct emission spectra of this fluorophore in the aqueous and lipid environments enable ratio-metric detection of PI(3,4)P₂ upon introduction of the probe into cells by microinjection. While the tool reported by Goulden et al. has all the advantages of the genetically encoded reporter (5), the solvatochromic probe additionally offers a convenient way to calibrate the signal for precise quantitation of PI(3,4)P₂ molar percentage on subcellular structures. Both studies demonstrate transient PI(3,4,5)P₃ kinetics and a more sustained PI(3,4)P₂ accumulation, which was linked to differential recruitment of Akt1 and Akt2 isoforms (1). Inhibition of SHIP2 significantly reduced PI(3,4)P₂ levels (1) and suppressed PI(3,4)P₂-dependent cell invasion (4), well in line with the model proposed by Goulden et al. (5).

What are the cellular degradation routes for PI(3,4)P₂? The lipid 4-phosphatases INPP4A/B were proposed to specifically inactivate PI(3,4)P₂ in various models (reviewed in 7), yet, unlike the 3-phosphatase PTEN, INPP4A/B deficiency alone was never sufficient to cause cellular

Department of Structural and Computational Biology, Max F. Perutz Laboratories, University of Vienna, Vienna, Austria.

Correspondence to Ivan Yudushkin: ivan.yudushkin@univie.ac.at.

© 2019 Yudushkin. This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see <http://www.rupress.org/terms/>). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 4.0 International license, as described at <https://creativecommons.org/licenses/by-nc-sa/4.0/>).

transformation. Data by Goulden et al. provide further support for the exciting new model where PI(3,4)P₂ is directly degraded by the PTEN phosphatase (4, 8), which would explain the high transformation and metastatic potential of PTEN deficiency.

While the set of tools developed by Goulden et al. offers important new insights into PI(3,4)P₂ dynamics in cells (5), as is often the case in science, many new intriguing questions arise. Several previous studies have reported localization-specific functions for PI(3,4)P₂ on various endosomal populations (1–3, 6); yet the cPH triple tandem probe reported by Goulden et al. is conspicuously absent from any vesicular structures (5). While accumulation of PI(3,4)P₂ on endosomes could well be cell type specific, it is tempting to speculate that PI(3,4)P₂ generated through class II PI3Ks could also have

distinct intracellular kinetics. Indeed, knockout of class II PI3K-C2γ, which is recruited to Rab5/App1-positive endosomes in response to insulin, led to significantly shorter Akt phosphorylation in primary hepatocytes (9). Conversely, fibroblasts lacking INPP4 showed sustained Akt phosphorylation in response to EGF, which typically induces only transient Akt activation (10), suggesting that the interplay between class I and II PI3K enzymes and lipid phosphatases at the plasma membrane and endosomal vesicles could define the cellular PI(3,4)P₂ dynamics and orchestrate downstream signaling.

Equally exciting is the question of the functional role of PI(3,4)P₂ in membrane trafficking and cell migration. PI(3,4)P₂ has been implicated in clathrin-mediated endocytosis, lamellipodia dynamics, and the formation of invadopodia (3, 4). It

would be interesting to test if these processes are coupled to intracellular trafficking of specific receptors and examine how exactly they are regulated by different PI3K enzymes. The new tools reported by Goulden et al. will undoubtedly spur new insights into how cells use lipids, such as PI(3,4)P₂, to organize signaling processes in space and time (5).

Acknowledgments

The author declares no competing financial interests.

1. Liu, S.-L., et al. 2018. *Mol. Cell.* 71:1092–1104.e5.
2. Marat, A.L., et al. 2017. *Science.* 356:968–972.
3. Posor, Y., et al. 2013. *Nature.* 499:233–237.
4. Fukumoto, M., et al. 2017. *Cancer Sci.* 108:941–951.
5. Goulden, B.D., et al. 2019. *J. Cell Biol.* <https://doi.org/10.1083/jcb.201809026>
6. He, K., et al. 2017. *Nature.* 552:410–414.
7. Li, H., and A.J. Marshall. 2015. *Cell. Signal.* 27:1789–1798.
8. Malek, M., et al. 2017. *Mol. Cell.* 68:566–580.e10.
9. Braccini, L., et al. 2015. *Nat. Commun.* 6:7400.
10. Ivetac, I., et al. 2009. *EMBO Rep.* 10:487–493.